ASCO: Gastric Cancer Outcomes Differ Based on Histologic Subtype

Share this content:

(ChemotherapyAdvisor) – Gastric cancer subtypes may be important predictors of patient outcome and response to treatment with bevacizumab, an exploratory analysis of 733 of 744 patients in the global phase 3 AVAGAST trial has found. In all regions, regardless of treatment, those with diffuse gastric cancer (type 2) had worse outcome than distal non-diffuse disease (type 3); median overall survival was 10.3 vs. 11.7 months (HR=0.82; 95% CI, 0.68–1.00), investigators reported during the ASCO 2012 Gastrointestinal Cancers Symposium.

Currently, gastric cancer subtypes are treated as a single disease. In the AVAGAST study, patients in the Americas and Europe showed more benefit of treatment with first-line capecitabine and cisplatin with or without bevacizumab than Asia-Pacific patients, Manish A. Shah, MD, of Memorial Sloan-Kettering Cancer Center, New York, NY, and colleagues reported. Type 2 gastric cancer (52.1%) was more common than proximal non-diffuse type 1 (9.5%) or type 3 (38.3%) in this study.

The poorest prognoses were observed in American and European patients, 8.0 vs. 11.1 months (HR=0.68; 95% CI, 0.53–0.89). However, these individuals were most likely to benefit most from treatment with bevacizumab vs. placebo: median OS for type 2 gastric cancer was 9.9 vs. 6.5 months (HR=0.68; 95% CI, 0.48–0.97) and type 3 median OS was 11.7 vs 9.0 months (HR=0.72; 95% CI, 0.48–1.07). In those with type 1 gastric cancer, median OS was 10.4 months for the bevacizumab arm vs. 12.8 months for placebo (HR=1.50; 95% CI, 0.77–2.93).

The investigators concluded that further prospective evaluation of gastric cancer subtypes is warranted.

Clinical Trial

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs